StockData
Insight Molecular Diagnostics Inc. logo

Insight Molecular Diagnostics Inc. (IMDX) stock

IMDXNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 7/30
$1.97+0.31 (+18.67%)

Close on Nov 20, 2026Market cap $64.47MP/E –Yield –

Insight Molecular Diagnostics free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Insight Molecular Diagnostics's free cash flow for the twelve months ending Jun 30, 2026 was -$31.00M. For fiscal 2025 it was -$25.37M. The highest annual figure on record is -$1.17M in fiscal 2014.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$25.37M–
FY2024Dec 31, 2024-$21.21M–
FY2023Dec 31, 2023-$23.61M–
FY2022Dec 31, 2022-$49.91M–
FY2021Dec 31, 2021-$38.19M–
FY2020Dec 31, 2020-$27.21M–
FY2019Dec 31, 2019-$20.63M–
FY2018Dec 31, 2018-$11.68M–
FY2017Dec 31, 2017-$13.48M–
FY2016Dec 31, 2016-$7.63M–
FY2015Dec 31, 2015-$4.73M–
FY2014Dec 31, 2014-$1.17M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$10.05M–
Q1 FY2026Mar 31, 2026-$8.25M–
Q4 FY2025Dec 31, 2025-$7.02M–
Q3 FY2025Sep 30, 2025-$5.68M–
Q2 FY2025Jun 30, 2025-$6.52M–
Q1 FY2025Mar 31, 2025-$6.15M–
Q4 FY2024Dec 31, 2024-$5.57M–
Q3 FY2024Sep 30, 2024-$5.62M–
Q2 FY2024Jun 30, 2024-$6.17M–
Q1 FY2024Mar 31, 2024-$3.85M–
Q4 FY2023Dec 31, 2023-$4.69M–
Q4 FY2022Dec 31, 2022-$10.45M–
Q3 FY2022Sep 30, 2022-$12.26M–
Q2 FY2022Jun 30, 2022-$12.37M–
Q1 FY2022Mar 31, 2022-$14.84M–
Q4 FY2021Dec 31, 2021-$7.47M–
Q3 FY2021Sep 30, 2021-$11.38M–
Q2 FY2021Jun 30, 2021-$8.67M–
Q1 FY2021Mar 31, 2021-$10.68M–
Q4 FY2020Dec 31, 2020-$6.31M–
Q3 FY2020Sep 30, 2020-$6.53M–
Q2 FY2020Jun 30, 2020-$7.45M–
Q1 FY2020Mar 31, 2020-$6.91M–
Q4 FY2019Dec 31, 2019-$6.21M–
Q3 FY2019Sep 30, 2019-$4.85M–
Q2 FY2019Jun 30, 2019-$2.85M–
Q1 FY2019Mar 31, 2019-$6.73M–
Q4 FY2018Dec 31, 2018-$2.46M–
Q3 FY2018Sep 30, 2018-$2.49M–
Q2 FY2018Jun 30, 2018-$3.97M–
Q1 FY2018Mar 31, 2018-$2.76M–
Q4 FY2017Dec 31, 2017-$3.35M–
Q3 FY2017Sep 30, 2017-$3.50M–
Q2 FY2017Jun 30, 2017-$3.32M–
Q1 FY2017Mar 31, 2017-$3.31M–
Q4 FY2016Dec 31, 2016-$2.60M–
Q3 FY2016Sep 30, 2016-$1.04M–

More Insight Molecular Diagnostics figures

See a number that looks wrong?